Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Aug;27(8):307-312.
doi: 10.1097/FPC.0000000000000292.

PharmGKB summary: pazopanib pathway, pharmacokinetics

Caroline F Thorn  1 , Manish R Sharma, Russ B Altman, Teri E Klein
Affiliations
Review

PharmGKB summary: pazopanib pathway, pharmacokinetics

Caroline F Thorn et al. Pharmacogenet Genomics. 2017 Aug.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of interest:

RBA is a stockholder in Personalis Inc. and a paid advisor to Pfizer and Karius. TEK is a paid scientific advisor to Rxight Pharmacogenetics.

Figures

Figure 1
Figure 1
Stylized diagram showing pazopanib metabolism and transport in the liver. A fully clickable version of this figure can be found at https://www.pharmgkb.org/pathway/PA166163407
See this image and copyright information in PMC

References

    1. Pick AM, Nystrom KK. Pazopanib for the treatment of metastatic renal cell carcinoma. Clinical therapeutics. 2012;34(3):511–520. - PubMed
    1. Ranieri G, Mammi M, Donato Di Paola E, Russo E, Gallelli L, Citraro R, et al. Pazopanib a tyrosine kinase inhibitor with strong anti-angiogenetic activity: a new treatment for metastatic soft tissue sarcoma. Critical reviews in oncology/hematology. 2014;89(2):322–329. - PubMed
    1. Sonpavde G, Hutson TE, Sternberg CN. Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma. Expert opinion on investigational drugs. 2008;17(2):253–261. - PubMed
    1. Kumar R, Knick VB, Rudolph SK, Johnson JH, Crosby RM, Crouthamel MC, et al. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Molecular cancer therapeutics. 2007;6(7):2012–2021. - PubMed
    1. de Wit D, van Erp NP, den Hartigh J, Wolterbeek R, den Hollander-van Deursen M, Labots M, et al. Therapeutic drug monitoring to individualize the dosing of pazopanib: a pharmacokinetic feasibility study. Therapeutic drug monitoring. 2015;37(3):331–338. - PubMed

Publication types

LinkOut - more resources